Sales of modern insulins increased by 28% (24% in local currencies).
Sales of NovoSeven® increased by 15% (11% in local currencies).
Sales of Norditropin® increased by 15% (9% in local currencies).
Sales in North America increased by 29% (17% in local currencies).
Sales in International Operations increased by 18% (16% in local currencies).
Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 28,500 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.